Friday, September 4, 2026

BioNTech halts Phase 2 colorectal cancer vaccine trial

BioNTech said on August 28, 2026 it is terminating the Phase 2 BNT122-01 trial of its individualized mRNA cancer vaccine autogene cevumeran as an adjuvant monotherapy in surgically resected, ctDNA-positive colorectal cancer, run with Genentech. An independent Data Safety Monitoring Board recommended stopping after finding a numerical imbalance in overall survival between the vaccine and watchful-waiting arms and judging further continuation unlikely to change the outcome, though it reported no new safety signal. BioNTech said the separate Phase 2 IMcode003 trial testing autogene cevumeran in combination with chemotherapy and checkpoint inhibition for pancreatic cancer is unaffected and continues as planned.

/ Sources

/ About this story

Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.

Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.

/ Related

Back to all news